Silvia Crescioli received her BSc in Biological Sciences (2007) and MSc in Cellular and Molecular Biology (2009) from the University of Florence. During her PhD, she focused on the identification and characterisation of new tumour associated antigens, as well as on the development and characterisation of murine monoclonal antibodies and engineered antibodies, such as scFv and bispecific diabodies, to target cancer cells. In 2014 she obtained her PhD in Biomedical Sciences, Experimental Oncology, and she then moved to UK to join King’s College London as a Postdoctoral Research Associate in the Cancer Antibody Discovery and Immunotherapy group led by Prof. Sophia Karagiannis.

Her research interests span across many areas of cancer immunology and immunotherapy such as: the study of the B cell response in cutaneous melanoma, as well as the isolation and characterisation of antibodies from cancer patients; antibody glyco-engineering and its effect on antibody effector function with particular focus on IgE isotype; and design and development of novel ADC for cancer immunotherapy.